Evidence map›Paper›PMID 17295306›Full record

ArticleEnvironmental and molecular mutagenesis2007

Assessing human germ-cell mutagenesis in the Postgenome Era: a celebration of the legacy of William Lawson (Bill) Russell.

Andrew J Wyrobek, John J Mulvihill, John S Wassom, Heinrich V Malling, Michael D Shelby, Susan E Lewis, Kristine L Witt, R Julian Preston, Sally D Perreault, James W Allen and 3 more

Open access · greenAbstract readConference Proceedings
In one paragraph

Article in Environmental and molecular mutagenesis, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Review
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Congenital anomalies in the children of cancer survivors: a report from the childhood cancer survivor study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Andrew J WyrobekLawrence Berkeley Laboratory, Berkeley, California, USA.
John J Mulvihill
John S Wassom
Heinrich V Malling
Michael D Shelby
Susan E Lewis
Kristine L Witt
R Julian Preston
Sally D Perreault
James W Allen
David M Demarini
Richard P Woychik
Jack B Bishop
National Institute of Environmental Health Sciences · USEnvironmental Protection Agency · USResearch Triangle Park Foundation · USJackson Laboratory · USLawrence Berkeley National Laboratory · USOak Ridge National Laboratory · USUniversity of Oklahoma Health Sciences Center · US

Funding

Genetic Consequences of Therapies for CancerR01CA104666 · NCI · VANDERBILT UNIVERSITY · PI BOICE, JOHN DUNNING · 2005 to 2009
$3.0M
MICROBICIDES: DEVELOPMENTAL CONTEXT OF ACCEPTABILITYR01HD040151 · NICHD · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI ROSENTHAL, SUSAN L · 2000 to 2004
$2.0M
NTP Center/The Evaluation Of Risks To Human ReproductionZ01ES100474 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI SHELBY, MICHAEL · 2002 to 2008
$1.5M
Assessing Human Germ Cell MutagenesisR13HD048151 · NICHD · JACKSON LABORATORY · PI HANDEL, MARY ANN · 2004 to 2004
$6k
Intramural NIH HHS Z99 ES999999NCI NIH HHS R01 CA104666NICHD NIH HHS R01 HD040151NICHD NIH HHS R13 HD040151NICHD NIH HHS R13 HD048151
6 · The paper itself

Abstract

Birth defects, de novo genetic diseases, and chromosomal abnormality syndromes occur in approximately 5% of all live births, and affected children suffer from a broad range of lifelong health consequences. Despite the social and medical impact of these defects, and the 8 decades of research in animal systems that have identified numerous germ-cell mutagens, no human germ-cell mutagen has been confirmed to date. There is now a growing consensus that the inability to detect human germ-cell mutagens is due to technological limitations in the detection of random mutations rather than biological differences between animal and human susceptibility. A multidisciplinary workshop responding to this challenge convened at The Jackson Laboratory in Bar Harbor, Maine. The purpose of the workshop was to assess the applicability of an emerging repertoire of genomic technologies to studies of human germ-cell mutagenesis. Workshop participants recommended large-scale human germ-cell mutation studies be conducted using samples from donors with high-dose exposures, such as cancer survivors. Within this high-risk cohort, parents and children could be evaluated for heritable changes in (a) DNA sequence and chromosomal structure, (b) repeat sequences and minisatellites, and (c) global gene expression profiles and pathways. Participants also advocated the establishment of a bio-bank of human tissue samples from donors with well-characterized exposure, including medical and reproductive histories. This mutational resource could support large-scale, multiple-endpoint studies. Additional studies could involve the examination of transgenerational effects associated with changes in imprinting and methylation patterns, nucleotide repeats, and mitochondrial DNA mutations. The further development of animal models and the integration of these with human studies are necessary to provide molecular insights into the mechanisms of germ-cell mutations and to identify prevention strategies. Furthermore, scientific specialty groups should be convened to review and prioritize the evidence for germ-cell mutagenicity from common environmental, occupational, medical, and lifestyle exposures. Workshop attendees agreed on the need for a full-scale assault to address key fundamental questions in human germ-cell environmental mutagenesis. These include, but are not limited to, the following: Do human germ-cell mutagens exist? What are the risks to future generations? Are some parents at higher risk than others for acquiring and transmitting germ-cell mutations? Obtaining answers to these, and other critical questions, will require strong support from relevant funding agencies, in addition to the engagement of scientists outside the fields of genomics and germ-cell mutagenesis.

Indexed as

Cost of IllnessGenetic Diseases, InbornGenome, HumanGerm CellsGerm-Line MutationHuman Genome ProjectHumansMutagenesis

Identifiers

PMID17295306
PMCPMC2071946
OpenAlexW2017647980

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.